Targeted delivery of chemotherapy with ultrasound and microbubbles - SONCHIMIO

CHRU TOURS0 个研究点目标入组 15 人开始时间: 2018年3月2日最近更新: 2018年3月26日

适应症

试验速览

暂无简介。

•- patient with non resectable liver metastases from colorectal cancer; patient with minimum two liver metastases which satisfy all the following criteria: diameter between 10 and 35 mm; arterially enhancing liver metastases detected with contrast enhanced ultrasound (CEUS); measurable liver metastases with CT-scan
•- age = 18 years;
•- ECOG/OMS 0-1;
•- life expectancy of at least 12 weeks;
•- adequate bone marrow, liver and kidney function;
•- written informed consent obtained from subject;
•- subjects covered by or having the rights to social security.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 15
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 15

•- Previous systemic or local treatment of liver metastases;
•- neo-adjuvant or adjuvant chemotherapy/radiotherapy in the 6 months prior to entering the study;
•- patient with resectable liver metastasis and no contraindication to hepatic resection;
•- indication for local ablative therapy (radiofrequency ablation or other validated hepatic-directed modality of treatment);
•- known contraindication to the injection of Sonovue®, of Gadolinium, of iodated contrast agent;
•- contraindication to MRI or perfusion CT scan;
•- Patient under legal protection;
•- Pregnant or lactating woman, or woman with ability to procreate and without contraception;
•- Inclusion in another therapeutic assay

发起方

CHRU TOURS